Congress Filed a Hemp Regulation Bill in January. It Never Left Committee.

Last checked 28 September 2026.

Affiliate disclosure: some links on this page are tracking links. If you buy through them we may earn a commission at no extra cost to you. It does not change our scores, our rankings or what we write. How we review.

The Short Verdict

There is a bill in Congress that would regulate hemp cannabinoid products instead of banning them. It is H.R. 7212, the Hemp Enforcement, Modernization, and Protection Act. It was introduced on 22 January 2026 by Rep. H. Morgan Griffith (R-VA-9). We read its status record on govinfo this morning. It lists three actions, every one of them dated 22 January 2026, and nothing after.

That is 249 days ago, by our count. In the same window, the hemp definition rewrite in section 781 moved to within 45 days of biting on one category of cannabinoid and, on our reading, 74 days of biting on the rest. The regulatory alternative has not had a hearing recorded against it.

If you buy hemp THC or CBD products, the practical read is unchanged: plan around the statute, not around the bill. H.R. 7212 is a real, bipartisan, live piece of legislation, and on the record we can see it has not moved an inch since the day it was filed.

What H.R. 7212 Is, From the Status Record

Everything in this section comes from BILLSTATUS-119hr7212.xml on govinfo, read on 28 September 2026. We asked the fetch to quote the last 200 characters it received; they fall inside the trailing dc:description metadata block, which is the end of the file. So the fields below are a complete record, not a truncated one.

Two of those three actions carry the identical text, “Introduced in House”. The file lists it twice. We quote it as found rather than tidy it.

The absence of a Congressional Research Service summary is worth naming, because it is the same shape of fact we reported on the Senate farm bill last week. A missing summary is a statement about the summary, not about the bill. It tells you CRS has not processed H.R. 7212. It tells you nothing about what is in the text.

Who Is On It — And Who Is On Three Hemp Bills At Once

Seven cosponsors, printed with their sponsorship dates:

Seven cosponsors, or eight supporters counting the sponsor. Four Republicans and four Democrats. Three of the eight are from Texas.

Two names travel across bills we have already covered on this site.

Rep. James Baird (R-IN-4) cosponsored H.R. 7212 on 11 February 2026. He is also the sponsor of H.R. 7010, the one-section bill from 12 January 2026 that would strike “365 days” from section 781 and insert “3 years”. And he is a cosponsor of H.R. 9830, the Lawful Hemp Protection Act, which he signed on 31 August 2026. Three hemp bills, three different approaches, one member on all of them.

Rep. Marc Veasey (D-TX-33) is the original cosponsor of H.R. 7212 and a cosponsor of H.R. 9830, which he signed on 30 July 2026.

We are describing an overlap in names on public documents. We are not describing a strategy, and none of these members has told us anything.

What the Bill Would Do — And Why We Are Quoting a Law Firm Instead of the Text

We could not read H.R. 7212’s operative text on this run. Two govinfo renderings of the introduced text both returned a permission error rather than the document. That is a different failure from a truncation: a truncated document gives you some of the text and hides the rest, while this gave us none of it. We are naming the failure mode rather than papering over it.

So what follows is not our reading of the bill. It is what Todd A. Harrison of Venable LLP published about it on 5 February 2026, quoted verbatim:

“In parallel, on January 22, 2026, Representatives Morgan Griffith (R-VA) and Marc Veasey (D-TX) announced the introduction of the Hemp Enforcement, Modernization, and Protection (HEMP) Act (H.R. 7212).”

“The bill would create a first-of-its-kind federal regulatory framework for hemp-derived cannabinoid products.”

The same note lists what the bill would require, again verbatim:

• “Require the U.S. Food and Drug Administration (FDA) to initiate rulemaking within three years of enactment to establish milligram limits for cannabinoid products”
• “Impose age restrictions on certain hemp-derived cannabinoid products”
• “Require labeling, facility registration, and product listing”
• “Direct FDA to establish manufacturing and third-party testing standards”

And: “If enacted, the legislation would significantly expand FDA’s authority over hemp-derived cannabinoid products.”

Note the sponsors’ own shorthand in that first quotation: they call it the HEMP Act. Search for that name and you will also find other bills using it. When you are checking this yourself, match on the bill number, not the nickname.

The Three-Year Problem

Set the two clocks side by side.

That is the whole tension in one table. The restriction has a date on the calendar. The alternative has a deadline measured from a starting gun nobody has fired.

There is a second three-year figure in this story, and it belongs to the same member. Baird’s H.R. 7010 would replace section 781’s “365 days” with “3 years”. Baird then cosponsored a bill whose rulemaking trigger, as described by Venable, is also three years. We are pointing at two numbers that match on the page. We make no claim about how either was chosen.

Energy and Commerce, Not Agriculture

H.R. 7212 was referred to one committee: House Energy and Commerce. Its govinfo policy area is Health.

That is a meaningful difference from everything else we have been tracking. The hemp definition lives in the Agricultural Marketing Act. The delay lives in an appropriations act. The Senate farm bill, S. 5526, is an Agriculture Committee product. H.R. 9830 drew referrals to four committees at once.

H.R. 7212 goes somewhere else entirely, because it amends the Federal Food, Drug, and Cosmetic Act. If you have been watching the Agriculture committees and the appropriations fight for news about hemp regulation, this is a bill that would never have shown up in your feed.

It also sits against a regulator that is already behind. FDA was directed to publish lists of cannabinoids within 90 days of enactment of Public Law 119-37, which put those lists due on 10 February 2026. By our count that is 230 days overdue as of today. Our standing description of the agency’s 2026 posture has not changed: FDA has issued no 2026 Federal Register rulemaking directed at cannabinoids. Its only 2026 Federal Register discussion of delta-8 THC appears as a supporting example in the preamble to a proposed rule about something else — the 11 August 2026 GRAS proposed rule, Docket FDA-2025-N-3262 — and FDA’s own cannabis page is still marked content-current as of July 2024.

A bill that hands FDA a large new job is a bill whose timetable depends on an agency that has missed the small job it already had.

The Calendar: Target Adjournment Is 18 December

We pulled the Senate’s own 2026 calendar PDF this morning, at senate.gov/legislative/resources/pdf/2026_calendar.pdf, and read it twice with different prompts. Its heading is “UNITED STATES SENATE / 119th Congress, 2nd Session / 2026 / TENTATIVE SCHEDULE”. Two lines on it matter:

“2ND SESSION CONVENES - JANUARY 5, 2026”

“TARGET ADJOURNMENT - DECEMBER 18, 2026”

The target adjournment date is seven days after 11 December, which is both the date section 2019 stops narrowing the hemp ban and the date the current funding runs out. It is 81 days from today.

This lines up with what we read on the HTML version of the tentative schedule yesterday, which prints a State Work Period from 5 October to 6 November and no State Work Period covering 11 December; the December period begins on the 21st. The PDF and the HTML page are two renderings of the same tentative schedule, and they agree.

Three limits, and we will keep printing them. The document calls itself tentative, and a tentative schedule is not a floor calendar. A target adjournment date is a target. And although this PDF does carry the legend the HTML page lacks — “Red days = Senate not in session” — we could not read the colour of any individual day out of a text extraction, so we still cannot tell you which November days are marked as non-session days. We know what the colours mean. We cannot see them.

Separately, we re-read the Senate floor schedule this morning. It shows two date headings: “Monday, Sep 28, 2026 / Convene at 3:00 p.m.” and “Thursday, Sep 24, 2026 / The Senate convened at 10:00 a.m. and adjourned at 4:05 p.m.” The words farm, agriculture, hemp, appropriations, continuing resolution and recess do not appear on it. That is the fifth consecutive day we have found it unchanged, and the agriculture extension lapses in two days.

Where This Sits Against the Two Dates

Our position has not moved, and we are not going to pretend a new bill changes it. The full reasoning is in which cannabinoids actually lose hemp status, and the running record is on our federal hemp deadline tracker.

In short: section 2019 of Public Law 119-103 carves in only two subclauses of section 781 until 11 December 2026. On our reading, that leaves cannabinoids a cannabis plant cannot naturally produce exposed from 12 November 2026, and everything else — including the 0.4 mg total-THC-per-container limit — arriving on 11 December 2026. Serious law firms read it the other way and put far more of the market on the November date. That split is real, and we set it out wherever we rely on it. Plan for 12 November and treat 11 December as upside.

The Senate was asked to remove section 2019 by name, in an amendment whose stated purpose was “To strike section 2019”, and it declined to do so on a 61-32 motion to table at 2:36 in the morning on 8 August. We wrote that up in full in the vote post. A motion to table is procedural: the correct reading is that the Senate declined to remove the provision when asked. It is not a statement that a majority of the chamber backed the delay as good policy.

What This Changes for Buyers Right Now

Honestly: very little, and that is the point worth taking away. A bill sitting in committee since January does not move your shipping window. The dates on the statute do.

What it does change is how you should read brand messaging. Several brands we recommend are telling customers to buy before December. Some of those same brands still carry 2018-era legality boilerplate in their footers. Both things can be true at once, and neither is a legal opinion. We wrote that up in three brands we recommend are telling you to stock up.

The single most useful number remains the container cap. The coming limit is 0.4 mg combined total per container — covering total THC plus other cannabinoids the FDA is required to list as having similar effects, a list the FDA has never published. “Container” is defined in the statute as the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product. That means a jar, not a gummy. Here is what that does to real products we have priced.

A 1.5 mg microdose gummy carries 112.5 times the coming per-container limit. This is not a rule aimed at high-dose products. It is a rule that a jar of very mild gummies fails by two orders of magnitude.

Jonathan Miller, general counsel of the U.S. Hemp Roundtable, put the same point this way to Harvest Public Media on 17 September 2026: “Even the vast majority of non-intoxicating CBD products have more than 0.4 milligrams of THC per container.”

The Brands, Their Prices, and What They Are Saying

Prices verified on the brands’ own pages on the dates shown. We publish list prices, not promo prices, because promo codes rotate. Scores are our own, and the full methodology is on how we review.

Three of the six brands print December language on their own storefronts. Three print none: Koi, Medterra and CBDfx. We are reporting what was on those pages on the dates shown, and brand banners change without notice.

One more thing we keep flagging because it is genuinely odd. Vena, Soul and Five each print a legality claim built on the 2018 Farm Bill on the same page that carries their own December warning. Soul’s homepage says hemp-derived THC is federally legal under the 2018 Farm Bill and also says Out of Office stops shipping on 11 December. We read that as boilerplate nobody has updated, not as anyone trying to mislead you.

Our Three Picks

Same picks as our other coverage this month. Nothing in H.R. 7212 changes a buying decision today.

1. Medterra — 8.8/10. The strongest all-round brand we cover and our top-scored. Subscribe & Save is a clean 25% off list on every SKU we have checked, which is rarer than it sounds. Full write-up: our Medterra review.
2. Soul — 8.6/10. The only brand we cover that prints a last-ship date in words with the year on its own product page. If you want the microdose format specifically, this is the one with a published end date. Full write-up: our Soul review. Note the 90, 180 and 360-count tiers read as prepaid bulk supplies rather than deliveries scheduled into 2027; we have not tested fulfilment, so read the terms.
3. CBDfx — 8.4/10. The best lab documentation of any brand we carry: per-strength, per-batch COAs with batch numbers and dates, archived back to 2020. If the coming rules make paperwork matter more, this is the one already doing it.

Lab Testing: What to Check Before December

If a bill like H.R. 7212 ever becomes law, third-party testing standards would be written by FDA. Until then the burden is entirely on you. Our guide to reading a COA walks through it properly; the short version for the next 74 days is to check the total THC per container figure, not the per-serving figure, because the per-container number is the one the statute uses.

Where the brands stand on documentation, from our own checks: CBDfx publishes per-batch, per-strength COAs with dates and a 2020-to-present archive, and you can see them at their lab reports page. Medterra publishes QR batch lookup and states openly that it does not test for herbicides or glyphosate. Five publishes public COAs. Vena is the weakest lab disclosure of any brand we carry: a Dropbox folder, no batch lookup, no lab named and no dates. We say so on our four big listicles and in our brands coverage, and we still rank it, because the products are good and the pricing is honest.

Buy If / Look Elsewhere

Buy now if: you use a hemp THC product regularly and want supply through the winter; you are in a state whose own law already bites before the federal dates, such as Illinois on 12 November, New Jersey in mid-November or Virginia on 1 November; or you want to try a format before the rules change. Buy from Koi or Vena if you want formats beyond gummies: Koi is the brand whose balm we rank in our topicals coverage, and Vena is the one selling THC seltzers, with its Happy Tonix line running $29.95 at 2 mg and $39.95 at 10 mg as checked on 23 September 2026.

Look elsewhere if: you were hoping this bill means the deadline is going away. It does not do that, and on the record we can see it is not moving. Also look elsewhere if you are shopping purely on cost per milligram — Soul Out of Office works out at about $0.12 per mg of CBD at list, the highest figure in our verified price set, and we would rather tell you that than sell you one.

Broader comparisons: all 12 brands we recommend, compared, plus our rankings for CBD gummies, delta-9 gummies, CBD oil and creams and topicals. State-by-state rules are in our state legality guide.

What We Could Not Verify

We would rather print this than let you assume we read more than we did.

• We have not read H.R. 7212’s operative text. Two govinfo renderings of the introduced bill returned a permission error on this run. Every description of the bill’s contents on this page is attributed to Venable LLP, dated 5 February 2026, and a law firm’s description of a bill is not the bill.
• We have not read S. 3686, another bill the same Venable note names. We are recording it as a lead, not citing it.
• We cannot read the colours on the Senate calendar PDF. The legend is printed. The shading is not recoverable from a text extraction, so we are not going to tell you which November days are marked.
• We have not read Title X of the Senate farm bill, S. 5526. That remains the highest-value document we have been unable to open, and we are not going to characterise what is or is not in it.
• Stock levels. We check prices from published pages, which do not reliably report availability. Check the brand’s own site before you count on a SKU.

FAQ

Does H.R. 7212 stop the hemp ban?
Not by itself, and not on any timetable we can point to. As of 28 September 2026 its status record shows three actions, all from 22 January 2026, and no hearing or markup among them.

Who sponsored it?
Rep. H. Morgan Griffith (R-VA-9), with Rep. Marc Veasey (D-TX-33) as original cosponsor. Venable’s note describes the two of them as announcing the introduction together.

Why is it in Energy and Commerce and not Agriculture?
Because it amends the Federal Food, Drug, and Cosmetic Act rather than the Agricultural Marketing Act. Its govinfo policy area is Health.

What actually changes on 12 November and 11 December 2026?
On our reading of section 2019, 12 November 2026 is when the exclusion bites for cannabinoids that cannot be naturally produced by a cannabis plant, and 11 December 2026 is when the rest of section 781 applies, including the 0.4 mg per-container limit. This is a contested reading and several law firms put far more of the market on the November date. Our full reasoning and the disagreement are both set out on the deadline tracker.

Is the Senate going to be around when this happens?
Its own tentative calendar prints a target adjournment of 18 December 2026 and no State Work Period covering 11 December. That is a tentative document and a target, not a guarantee, and we are not going to predict the floor schedule from it.

How do I check any of this myself?
The status record is BILLSTATUS-119hr7212.xml in govinfo’s bulk data. The calendar is senate.gov/legislative/resources/pdf/2026_calendar.pdf. Both are free and neither needs an account.

Sources

• govinfo bulk data, BILLSTATUS/119/hr/BILLSTATUS-119hr7212.xml — read 28 September 2026, boundary-checked.
• U.S. Senate, Tentative Schedule, 119th Congress 2nd Session, 2026 (PDF) — read twice, 28 September 2026.
• U.S. Senate floor schedule — read 28 September 2026.
• Todd A. Harrison, Venable LLP, Building on Recent Hemp Reforms, Congress Considers Further Federal Oversight of Cannabinoid Products, 5 February 2026.
• Public Law 119-103, section 2019; Public Law 119-37, section 781.
• Skyler Rossi, Harvest Public Media, 17 September 2026 (Jonathan Miller quotation).
• Brand storefronts for Medterra, Soul, Five, Vena, Koi and CBDfx — prices and banners checked on the dates given in the table.

Nothing here is legal advice. Hemp rules differ by state and are changing quickly. Check your own state’s rules and the brand’s shipping policy before you order. Last checked 28 September 2026 — we update this page as the record changes.

Affiliate disclosure: some links on this page are tracking links. If you buy through them we may earn a commission at no extra cost to you. It does not change our scores, our rankings or what we write. How we review.

Want the running version? Our federal hemp THC deadline tracker is updated as documents land, and Medterra remains our highest-scored brand at 8.8/10.